These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2159365)

  • 1. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.
    Woessner RD; Chung TD; Hofmann GA; Mattern MR; Mirabelli CK; Drake FH; Johnson RK
    Cancer Res; 1990 May; 50(10):2901-8. PubMed ID: 2159365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.
    Woessner RD; Mattern MR; Mirabelli CK; Johnson RK; Drake FH
    Cell Growth Differ; 1991 Apr; 2(4):209-14. PubMed ID: 1651102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
    Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
    Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thy-1 as a negative growth regulator in ras-transformed mouse fibroblasts.
    Sugimoto Y; Ikawa Y; Nakauchi H
    Cancer Res; 1991 Jan; 51(1):99-104. PubMed ID: 1670996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
    Sullivan DM; Latham MD; Ross WE
    Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
    Chen M; Beck WT
    Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
    Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
    Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
    Webb CD; Latham MD; Lock RB; Sullivan DM
    Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
    Tortora G; Ciardiello F; Damiano V; Pepe S; Bianco C; di Isernia G; Davies SL; North P; Harris AL; Hickson ID
    Clin Cancer Res; 1995 Jan; 1(1):49-56. PubMed ID: 9815886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential growth factor expression in transformed mouse NIH-3T3 cells.
    Ciardiello F; Valverius EM; Colucci-D'Amato GL; Kim N; Bassin RH; Salomon DS
    J Cell Biochem; 1990 Jan; 42(1):45-57. PubMed ID: 1967612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M; Beck WT
    Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival.
    Xin H; Geng Y; Pramanik R; Choubey D
    J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
    Wolverton JS; Danks MK; Granzen B; Beck WT
    Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recessive (mediator-) revertants from c-H-ras oncogene-transformed NIH 3T3 cells: tumorigenicity in nude mice and transient anchorage and serum independence of the recovered tumor cells in culture.
    Omata-Yamada T; Yamada H; Lengyel P
    J Cell Physiol; 1991 Nov; 149(2):214-21. PubMed ID: 1748716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
    Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
    Friche E; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.